SEARCH

SEARCH BY CITATION

References

  • 1
    Principles of a Sound Drug Formulary System [Internet]. Alexandria (VA): Academy of Managed Care Pharmacy, 2000 Oct. Available from: http://www.amcp.org/publications/drugformulary.pdf.
  • 2
    Gibson JL, Martin DK, Singer PA. Priority setting for new technologies in medicine: a transdisciplinary study. BMC Health Serv Res 2002;2: article 14.
  • 3
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 4
    Langley PC, Sullivan SD. Pharmacoeconomic evaluations: guidelines for drug purchasers. J Managed Care Pharm 1996;2: 6717.
  • 5
    Mather DB, Sullivan SD, Augenstein D, et al. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. Am J Manag Care 1999; 5: 27785.
  • 6
    Sullivan SD, Lyles A, Luce B, Gricar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefit management organizations. J Manag Care Pharm 2001;7: 27282.
  • 7
    Foundation for Managed Care Pharmacy. Response to Comments Regarding AMCP's Format for Formulary Submissions [Internet]. Alexandria (VA): The Foundation, 2002 Oct. Available from: http://www.fmcpnet.org/data/resource/comments.pdf.
  • 8
    U.S. Food and Drug Administration. FDA Modernization Act [Internet]. Washington: The Administration, 1997 Nov 21. Available from: http://www.fda.gov/opacom/7modact.html.
  • 9
    Daniels N. Four unsolved rationing problems. Hastings Center Rep 1994;24: 279.
  • 10
    Richardson J, McKie J. The Rule of Rescue [Internet]. Working paper 112. West Heidelberg, Australia: Centre for Health Program Evaluation, 2000. Available from: http://chpe.buseco.monash.edu.au/pubs/wp112.pdf.
  • 11
    Pharmaceutical Benefits Scheme. 1995 Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Major Submissions Involving Economic Analyses [Internet]. Canberra, Australia: Commonwealth Department of Health and Aged Care, 1995 modified 2002 Jan 13. Available from: http://www.health.gov.au/pbs/pubs/pharmpac/gusubpac.htm.
  • 12
    Interim Document to Accompany Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Major Submissions Involving Economic Analyses [Internet]. Canberra, Australia: Commonwealth Department of Health and Aged Care, 2000 Apr. Available from: http://www.health.gov.au/pbs/pubs/pharmpac/interim/.
  • 13
    Canadian Coordinating Office of Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada [Internet] (2nd ed.). Ottawa, Ontario, Canada: The Office, 1997. Available from: http://www.ccohta.ca/entry_e.html.
  • 14
    National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors [Internet]. London: The Institute, 2001 Jun. Available from: http://www.nice.org.uk/pdf/technicalguidanceformanufacturersandsponsors.pdf .
  • 15
    Drummond M. Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness? [editorial] Appl Health Econ Health Policy 2002;1: 34.
  • 16
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313: 27583.
  • 17
    Task  Force  on  Principles  for  Economic  Analysis of Health Care Technology. Economic analysis of health care technology. Ann Intern Med 1995;123: 6170.
  • 18
    Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324: 13625.
  • 19
    Johannesson M, Jönsson B, Göran K. Outcome measurement in economic evaluation. Health Econ 1996;5: 27996.
  • 20
    Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies: an appraisal of the literature. Pharmacoeconomics 1997;11: 7588.
  • 21
    Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 35461.
  • 22
    Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. Oxford: Oxford University Press, 1987.
  • 23
    Glick H, Kinosian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. Drug Inf J 1994;28: 691707.
  • 24
    Henry D. Economic analysis as an aid to subsidisation decisions. The development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992;1: 5467.
  • 25
    Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994; 331: 66970.
  • 26
    Sheldon TA. Problems of using modeling in the economic evaluation of health care. Health Econ 1996;5: 111.
  • 27
    Daniels N, Sabin JE. The ethics of accountability in managed care reform. Health Affairs 1998;17: 5064.